| Released | Contributor | Author | Title | Pages | Price |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ACADIA PHARMACEUTICALS INC (ACAD=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ACADIA PHARMACEUTICALS INC (ACAD=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for MEDICAL SUPPLIES | 18 |
$49 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ACAD: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | ACADIA PHARMACEUTICALS INC (ACAD=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ACAD | 13 |
$25 |
| 21-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: ACADIA PHARMACEUTICALS INC | 5 |
$25 |
| 21-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| ACADIA Pharmaceuticals | 5 |
$25 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACAD , CSII , CERS , CRXX , GTXI , SGMO , UGNE -- DRUGS | 3 |
$4 |
1.48% Nasdaq 
Research Reports
